Setting new standards in information exchange for the pharmaceutical and biotech industry
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Learn more at www.adaptivebiotech.com
Imaging Endpoints (IE) is a mission driven research and imaging CRO with offices in Scottsdale, Arizona and Waltham, Massachusetts. We specialize in providing the industry’s leading imaging expertise and most advanced technologies coupled with exquisite services. Our experience extends from translational to phase 3 trials and every step in-between. Our organization is unique in that it is owned by a team of over 40 in-house radiologists and nuclear medicine physicians that specialize in advanced imaging technologies. Our comprehensive services span all aspects of trial planning and conduct, including protocol development, site qualification and standardization, real-time image receipt/QC and reads, data management, regulatory compliance and preparation for meetings/submissions to regulatory authorities. Our Rapid Detection and Assessment of Response program (RaDAR) is designed to accelerate product development by integrating the most advanced imaging technologies into clinical trials. At Imaging Endpoints, our capabilities go above and beyond the typical imaging core lab offering. Learn more at www.imagingendpoints.com.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound. Founded in 2010, Mitra is headquartered in Boston and maintains a significant research and laboratory presence in Bangalore, India. Visit us at www.mitrabiotech.com.
NanoString Technologies provides life science tools for translational research and molecular diagnostics. nCounter® digital molecular barcoding enables simultaneous measurement of hundreds of genes, miRNAs, proteins, or copy number variations. Precise and highly sensitive, this technology facilitates numerous applications including NanoString’s first diagnostic product, the Prosigna® Prognostic Breast Cancer Gene Signature Assay. Learn more at www.nanostring.com.
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the US, but work hard to maintain easy access and all the efficiencies of a smaller operation. Visit www.neogenomics.com.
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. Based on its worldwide unparalleled Know How in TNF ligands, the company has built a promising pipeline of drug candidates that target different TNFSF (tumor necrosis factor superfamily)-dependent signaling pathways, thereby restoring the immune response against tumors. TNFSF receptors and the respective ligands are of great importance in the anti-tumor immune process. Their diverse expression pattern in various immune cells highlights the critical role that TNFSF receptors play in many parts of the body and in the various phases of the anti-tumor immune response. The TNFSF ligands stimulating receptor signaling naturally exist as homo-trimers with three receptor binding sites. This trivalent structure of the TNFSF proteins and the resulting receptor clustering are prerequisites for the transmission of a signal delivered into the cell. TNFSF-mediated signaling induces a wide range of biological effects, including programmed cell death (i.e., apoptosis), proliferation, differentiation, and tumor growth. Learn more about us at http://apogenix.com/en.
BeiGene is a global biotechnology company focused on the discovery and development of innovative drugs to treat cancer. Our drug discovery engine has generated four assets entering late-stage clinical development, as well as several drugs in preclinical development. Each program has potential meaningful differentiation, and our broad portfolio offers opportunities for combinations. BeiGene has access to huge numbers of patients in China that enable us to better identify therapies with the potential to be best-in-class treatments. Learn more at www.beigene.com.
Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company’s cloud-based offerings include medical imaging, cardiac safety, clinical adjudication, randomization and trial supply management and optimization, electronic and eSource data capture, site payments and forecasting, pharmacovigilance, trial management, and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development. The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the US, Europe, and Asia. Learn more about us at www.bioclinica.com.
Boston Immune Technologies & Therapeutics, Inc (BITT) is a first in class oncology company targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment that protect tumors and play a role in resistance to checkpoint inhibitors including PD1 and CTLA4. TNFR2 is also expressed on the surface of certain cancers as an NFkB-driven growth receptor oncogene. BITT’s antibody technology was developed at Massachusetts General Hospital/ Harvard Medical School. Learn more about us at www.bostonimmunetech.com.
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India, Australia and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Learn more about us at www.cgix.com.
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized cell-based therapies targeting life-threatening diseases. Celyad’s Natural Killer Receptor based T-Cell platform has the potential to treat a broad range of tumors. CYAD-01 is being evaluated in the THINK open-label Phase I study to assess the safety & clinical activity of multiple administrations of autologous CYAD-01 cells in 7 refractory cancers. Learn more about us at www.celyad.com.
Cofactor is a biotechnology & software company using RNA as the foundation for a better understanding of disease. We’ve developed tools to quantify complex molecular profiles including gene expression, tumor infiltrating lymphocytes, and mutational burden, from a single FFPE specimen. We offer translational/clinical assays, database development, & custom assay design. Learn more at www.cofactorgenomics.com.
Cytel is shaping the future of drug development. As the world’s largest Biometrics CRO, we improve our customers’ chances of success through expert trial design, efficient operational implementation and reliable clinical data management. Learn about our clinical research services capabilities, in addition to the Cytel line of statistical and operations-support software at www.cytel.com.
Defined Health is a leading biopharmaceutical asset development strategy consultancy with 25+ years of experience. Our consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. Our clients include top global pharma, large cap biotech, specialty pharma and hundreds of pre-commercial biotech and platform technology companies. Our work encompasses asset evaluation, early commercial strategy, indication prioritization and sequencing, life-cycle management and search and evaluation. Learn more at www.definedhealth.com.
Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, Ill. Learn more about us at www.exicuretx.com.
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees. Further information is available at www.iconplc.com.
KIYATEC prioritizes accurate ex vivo prediction of patients’ drug response, focused primarily on data correlation to human clinical outcomes. Our drug response profiling services utilize phenotypic 3D cell-based models for predicting patient response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating the efficacy of both immuno-oncology therapies and chemotherapeutics. For more information, please visit us at www.kiyatec.com.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 55,000 employees worldwide. Learn more at www.iqvia.com.
Oncorus is a biotechnology company developing innovative and impactful, next-generation oncolytic viral products with unprecedented potential to recruit all arms of the immune system. Learn more about us at http://oncorus.com.
As a leading central review core lab for clinical trials, PAREXEL offers multiple solutions to standardize central oncology endpoint assessments. With PAREXEL you are supported by our in-house medical scientific and medical writing expertise, complemented by specialized key opinion leaders and scientific advisors in oncology. For more information, visit www.PAREXEL.com.
Personalis, Inc provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.Visit our website at www.personalis.com and follow @PersonalisInc.
Learn more about us at www.replimune.com.
SmartAnalyst is positioned at the core of bio-pharma innovation: our strategic consulting services help our clients to shape the next generation of innovative therapies to improve patient outcomes and garner market success. By supporting strategic decisions at the tumor, asset and portfolio levels, our consulting services and data-driven insights help leading immuno-oncology companies to develop forward-looking strategies for clinical differentiation and success. Learn more about us at www.smartanalyst.com.
Axio Research offers a comprehensive range of statistical genetics and genomics services to clients undertaking drug discovery and companion diagnostics development. Merging deep experience in statistical genetics, bioinformatics, and biostatistics with clinical understanding, Axio applies leading-edge statistical and computational methods to support and expedite genomic discovery. Reach us at: info@AxioResearch.com. Learn more about us at www.axioresearch.com.
Caprion is a specialty CRO providing laboratory services to pharmaceutical/biotechnology companies with GCP/GLP/GCLP capabilities. Caprion’s ImmuneCarta® Division, offers multi-parametric flow cytometry, cytokine testing, and ELISpot for analyses of innate and adaptive immune responses. Caprion’s ProteoCarta™ Division leverages its expertise in mass spectrometry for protein analysis in support of biomarkers development. Learn more about us at www.caprion.com.
Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485 and ISO 22301 certified and GAMP® 5 compliant medical imaging core lab. At Intrinsic, we have the team, the technology and the therapeutic expertise to manage your entire medical imaging trial providing comprehensive services in support of Phase I-IV Clinical Trials. For more information, please visit www.intrinsicimaging.com.
Provecs Medical is an innovative immune-oncology company founded in Hamburg, Germany. Provecs develops unique multivalent immunotherapeutics to reprogram the tumour microenvironment. Core technologies: the adenoviral platform ENVIRO and the proof-of-concept platform EXVIRO for lead identification and qualification applying high through-put technologies like transcriptome profiling, bioinformatics, and tissue immune imaging technologies. Learn more at www.provecs.com.